To evaluate prognostic factors that could affect disease-free survival and recurrence after liver resection for hepatocellular carcinoma (HCC) on cirrhosis.
Objective
To evaluate prognostic factors that could affect disease-free survival and recurrence after liver resection for hepatocellular carcinoma (HCC) on cirrhosis.
Summary Background Data
Tumor recurrence is the main cause of poor survival after liver resection for HCC on cirrhosis.
Methods
Two hundred twenty-four liver resections for HCC on cirrhosis were retrospectively reviewed. Univariate and multivariate analyses were performed on several clinicopathologic variables to analyze factors affecting long-term outcome and intrahepatic recurrence. The relation between preoperative aminotransferase level and recurrence rate was evaluated in the overall group, and separately in HCV-positive and in HBsAgpositive patients. Median follow-up was 35.6 months.
Results
The 1-, 3-, and 5-year overall survival rates were 83%, 62.8%, and 42.5%, respectively. The 1-, 3-, and 5-year dis-ease-free survival rates were 70.3%, 43%, and 27.4%, respectively. The 1-, 3-, and 5-year recurrence rates were 20.8%, 38.6%, and 54.4% respectively. Tumor recurrence appeared in 93 patients (41.5%) and was the main cause of death in 51 patients (56%). Number of nodules, tumor capsule, microvascular portal vein thrombosis, and preoperative serum aspartate aminotransferase (AST) level significantly affected disease-free survival and recurrence rates. On multivariate analysis, single nodules and preoperative AST level less than twice normal (2N) were related to a better 5-year disease-free survival and lower tumor recurrence. In particular, among HCV-positive patients the recurrence rate was strongly affected by the preoperative AST level.
Conclusions
Child A patients with single nodules are the best candidates for liver resection. Tumor recurrence is strictly linked to the status of the underlying liver disease, and a preoperative AST level equal to 2N seems to be a sensitive cutoff among patients with different risks of recurrence. HCV-positive patients with AST levels above 2N have the highest risk for intrahepatic recurrence and should be monitored carefully or offered alternative treatments.
Hepatocellular carcinoma (HCC) is one of the most frequent malignant tumors in the world 1 and is related to hepatitis B or C virus infection in 80% of cases. 1, 2 Because of recent progress in early diagnosis and operative tech-nique, results after liver resection have improved, with a 5-year survival rate of up to 50% and a mortality rate of less than 2%. 3, 4 However, long-term survival remains unsatisfactory because of the high incidence of tumor recurrence (the main cause of poor prognosis), which ranges from 60% to 100% at 5 years. [5] [6] [7] [8] To improve the surgical result for HCC and to evaluate whether any adjuvant treatment might be useful and prolong disease-free survival, it is of paramount importance to elucidate the presence of possible risk factors for recurrence.
It has been already shown that patients with high preoperative serum aminotransferase levels are at increased risk for postoperative morbidity and mortality after liver resection. 9, 10 Recently, Japanese authors have reported that cirrhotic patients with serum aminotransferase levels persistently greater than twice the normal levels (2N) are at high risk for HCC. 11 However, the role of preoperative aminotransferase levels as an index of long-term prognosis in resected patients is still unknown.
We retrospectively reviewed our experience with 224 liver resections for HCC on cirrhosis to evaluate prognostic factors that might affect disease-free survival and recurrence rates. Special care was taken to analyze the relationship between preoperative aminotransferase levels, as an index of chronic active hepatitis and liver inflammation, and tumor recurrence in the global series and separately in HCV-positive and in HBsAg-positive patients.
METHODS
From August 1983 to December 1999, 285 curative liver resections for HCC on cirrhosis were performed at the Department of Surgery and Transplantation, University of Bologna, Italy. Most of them have been included in another report from this department. 4 The first aim of this study was to evaluate the influence of common clinicopathologic variables on recurrence and disease-free survival rates among resected patients for HCC on cirrhosis in our single-center experience. The second one was to analyze the relationship between preoperative serum aminotransferase levels and long-term outcome in the same group of patients. Twenty-one patients were lost to follow-up and 10 patients who died within 30 days after surgery (operative mortality) were not included in the analysis. Since the entire set of laboratory data were not available in 30 patients, they were also excluded from the study. A total of 224 liver resections for HCC on cirrhosis were thus considered for our retrospective analysis.
There were 182 (81.2%) men and 42 (18.8%) women. Median age was 62.5 Ϯ 8.2 years (range 22-79 years). The cause of cirrhosis was postnecrotic (HBsAg or anti-HCV positive) in 161 (71.8%), alcoholic in 15 (6.7%), and others in 48 (21.4%) patients. Thirty-two (14.3%) patients were HBsAg positive, while 129 (57.6%) patients were anti-HCV positive. In 59 (26.3%) cases, the liver resection was performed before 1990, and the serum determination of anti-HCV antibodies was not available at that time. Clinicopathologic characteristics are summarized in Table 1 .
For the evaluation of liver function, we routinely used the Child-Pugh classification. 12 Accordingly, 185 (82.6%) patients were Child A, 37 (16.5%) Child B, and 2 (0.9%) Child C. The distribution of Child stages within different etiologic groups is reported in Table 2 . From February 1993, liver insufficiency in cirrhotic patients was also studied with the lidocaine (MEGX) test, which was included in the standard evaluation panel. The procedure for carrying out this test and the results obtained have been published elsewhere. 13 Location of the HCC and its relation to intrahepatic vessels were examined by liver ultrasonography and abdominal spiral CT scan. In 161 (71.9%) cases, angiography of the celiac trunk was carried out, and in 98 (43.8%) patients an intra-arterial injection of Adriamycin, Mitomycin, and Lipiodol was administered to induce tumor necrosis and improve long-term results after liver resection.
The type of procedure performed was defined according the classification of hepatic segments by Couinaud. 14 The procedure was defined as a major hepatectomy when three or more segments were resected. Resection was considered curative when the entire tumor was macroscopically resected and the surgical margin was microscopically free from tumor invasion. None of the patients was enrolled in any prospective trial of postoperative adjuvant therapy.
Prognostic Factors
The following clinicopathologic variables that might correlate with disease-free survival and recurrence rates were evaluated: presence of HBsAg marker, presence of anti- HCV antibodies, Child classification, ␣-fetoprotein level, diameter of nodules (Ͻ5 cm vs. Ͼ5 cm), number of nodules (single vs. multiple), preoperative intra-arterial chemoembolization, type of resection, intraoperative blood transfusion, micro-or macroscopic portal vein infiltration, presence of tumor capsule, and preoperative aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels (Tables 3  and 4 ). The relation between preoperative aminotransferase levels and recurrence rate was then analyzed selecting only anti-HCV-positive and HbsAg-positive patients, respectively.
The cutoff level between patients with low and high inflammatory activity (reflected by aminotransferases) was considered 2N. 11 Depending on preoperative aminotransferase levels, we used the following terms: AS1, AST less than 80 U/L; AS2, AST more than 80 U/L; AL1, ALT less than 80 U/L; AL2, ALT more than 80 U/L.
Follow-Up
Follow-up ended on April 30, 2000. Patients were followed after liver resection at the outpatient clinic every 3 months with measurement of serum ␣-fetoprotein level and hepatic ultrasonography, and every 6 months with chest x-ray. When recurrence was suspected, further evaluations were made by abdominal CT scan and/or angiography of the celiac trunk with Lipiodol injection and, if necessary, by ultrasound-guided biopsy to confirm the diagnosis. Our policy and results for the treatment of tumor recurrence have been reported elsewhere. 4
Statistical Analysis
The results were expressed as median Ϯ standard deviation. Regarding the analysis of prognostic factors, the survival curves were obtained by the Kaplan-Meier method, and the differences in survival between the groups were compared by the log-rank test. Survival was considered from the day of surgery to the day of death or the most recent follow-up visit. The recurrence rate was computed from the day of surgery to the first follow-up visit that revealed tumor recurrence. Disease-free survival was defined as the combination of the two variables mentioned, considering the date of death or the date of tumor recurrence as the time of terminal events. After the univariate analysis of the factors affecting disease-free survival and recurrence, only the significant variables were used in the multivariate analysis using the Cox proportional hazard model. P Ͻ .05 was considered statistically significant. Statistical analysis was carried out using SPSS. 15
RESULTS

Surgical Procedures
Surgical procedures consisted of 67 (29.9%) wedge resections, 135 (60.3%) segmentectomies, and 22 (9.8%) major hepatectomies. 
Survival, Recurrence Rate, and Disease-Free Survival
The median follow-up was 35.6 months (range 3-128). The 1-, 3-, and 5-year overall survival rates were 83%, 62.8%, and 42.5%, respectively ( Fig. 1 ). Tumor recurrence appeared in 93 (41.5%) patients and was the leading cause of death (51 patients, 56%). The 1-, 3-, and 5-year recur- Table 2 ), presence of multiple nodules (P Ͻ .01), absence of tumor capsule (P Ͻ .05), presence of microvascular portal vein thrombosis (P Ͻ .05), and preoperative AST level greater than 2N (P Ͻ .001) were found to be significantly related to a higher incidence of tumor recurrence. The 5-year recurrence rate was not influenced by the presence of HBsAg marker, anti-HCV antibodies, ␣-fetoprotein level, preoperative chemoembolization, type of resection, intraoperative blood transfusion, tumor diameter, or preoperative ALT level.
When the multivariate analysis was conducted including the significant variables obtained on univariate analysis, preoperative AST levels and number of nodules showed an independent statistically significant relationship to recurrence rate (P Ͻ .0001, and P Ͻ .01, respectively). The influence of preoperative AST levels and number of nodules on recurrence rate are shown in Figure 2 .
As reported in Table 3 , on univariate analysis, number of nodules (P Ͻ .001), microvascular portal vein infiltration (P Ͻ .05), tumor capsule (P Ͻ .05), and preoperative AST levels (P Ͻ .001) were found to be significantly related to tumor-free survival. It was slightly influenced by preoperative ALT levels (P ϭ .08) but was not related to ␣-fetoprotein level, tumor diameter, presence of anti-HCV antibodies or HBsAg marker, preoperative chemoembolization, type of resection, or blood transfusion. On multivariate analysis, AS1 status and single nodules again showed an independent significant relationship to a better 5-year disease-free survival (P Ͻ .001, and P Ͻ .01, respectively). Disease-free survival curves based on preoperative AST levels and number of nodules are shown in Figure 3 .
Preoperative Serum Aminotransferase Levels and Recurrence Rate
The 5-year recurrence rate was 46% among AS1 patients and 74% in AS2 patients (P Ͻ .001), showing a markedly negative influence of high preoperative AST level on tumor recurrence (see Fig. 2 ). Among AL1 patients, the 5-year recurrence rate was 50%; among AL2 patients, it was 61% (P ϭ NS).
HCV-Positive Patients
In the HCV-positive group, 5-year recurrence was 38.5% in AS1 patients and 74.7% in AS2 patients (P Ͻ .01); in the AL1 group the rate was 47.6% and in AL2 patients it was 68.5% (P ϭ .05). Tumor recurrence appeared in 42 (32.6%) patients; in 27 (64.3%) of them, the preoperative AST level was higher than 2N. Relapse of disease developed in 15 (20.8%) patients in the AS1 group and in 27 (45.8%) in the AS2 group. The incidence of tumor recurrence between AS1 and AS2 patients was significantly different (P ϭ .01). Tumor recurrence appeared in 15 (24.2%) AL1 patients and in 27 (39.1%) AL2 patients (P ϭ .05).
HBsAg-Positive Patients
Among the 32 HbsAg-positive patients, 13 (40.6%) experienced tumor recurrence; there were 8 (34.7%) patients in the AS1 group and 5 (55.5%) in the AS2 group (P ϭ NS). Nine (39.1%) patients were in the AL1 group and 4 (44.5%) were in the AL2 group (P ϭ NS). There was no difference in tumor relapse between AS1 and AS2 patients, or between AL1 and AL2 patients.
DISCUSSION
In the present series, disease-free survival was significantly longer in patients with single nodules, complete tumor capsule, no portal vein infiltration, and low aminotransferase levels. Most liver resections for multiple HCCs were performed at the beginning of our experience, and we have recently advocated surgical treatment only for Child A patients with a single tumor. 4 It has already been reported that almost all patients with two or more HCCs develop intrahepatic recurrence within 5 years, since they might have HCCs of multicentric origin. 8 In the present study, there were no 4-year survivors among patients with more than one nodule. Patients with multiple tumors are therefore offered treatments other than surgery, such as ethanol injection, arterial chemoembolization, or liver transplantation. 16, 17 The finding that vascular neoplastic thrombosis affect prognosis is not new, since its presence has been advocated as the common method of intrahepatic spread that is at the origin of early intrahepatic recurrence. 18 -20 This type of dissemination is usually known as "intrahepatic metastasis." Unfortunately this well-known risk factor can be investigated only in resected specimens and not during the preoperative evaluation.
According to the experience gained at the University of Bologna, overall survival after liver resection for HCC has increased because of improvements in the early detection of tumors and in surgical techniques. 3, 4, 21, 22 However, longterm results are not fully satisfactory because of tumor recurrence, the main cause of poor prognosis. [5] [6] [7] [8] Many investigators have already reported that tumor size, satellite nodules, surgical margin, and ␣-fetoprotein levels are related to a high incidence of tumor recurrence. 7, 8, 18, 23 In the present series, tumor recurrence was the main cause of death, and it appeared in more than 40% of the resected patients. On univariate analysis, the recurrence rate was significantly affected by number of nodules, tumor capsule, microvascular tumor thrombosis, and preoperative AST levels, as in the evaluation of disease-free survival.
The principal interest in this study is that on multivariate analysis, the only variables markedly associated with better disease-free survival and low incidence of tumor recurrence are the presence of single nodules and preoperative AST level less than 2N.
Recurrence of HCC is thought to derive from intrahepatic metastases through the portal vein, 18, 24 as already discussed, and more frequently from metachronous multicentric carcinogenesis in the remnant liver. 19, 24, 25 After liver resection for HCC, a few Japanese reports have pointed out that chronic active hepatitis and cirrhosis are the most significant risk factors for intrahepatic recurrence thorough multicentric carcinogenesis, the so-called "multicentric occurrence." 16, 21, 26 This can be explained by the fact that repeated inflammation and cellular necrosis in patients with chronic hepatitis or cirrhosis enhance proliferating activity (mitosis) and accelerate the development of new foci of HCC, by an increased rate of random mutations and promotion due to gene instability. 27, 28 In cirrhotic patients, the aminotransferase serum level is usually considered an index of the activated inflammatory activity that reflects the etiopathogenetic mechanism of hepatocyte necrosis. 11 For these reasons, several authors have investigated the efficacy of interferon therapy, as an agent modulating inflammatory response, to prevent HCC in patients with HBV-or HCV-related liver disease. 26, 29, 30 Interferon treatment has been shown to reduce the incidence of HCC in "responder" patients (patients with a decrease to normal range of aminotransferase levels after interferon treatment). 26, 29, 30 In "nonresponders" the risk of developing an HCC remains similar to that in nontreated patients. 26, 30 Hypertransaminasemia is the clinical expression of a biologic activity at the basis of the multicentric carcinogenesis. In an experimental model, Marks et al. demonstrated that vigorous necrosis is the cause of intensive proliferation of tissue cells, which correlates to the development of multicentric carcinogenesis by an increased rate of mutations and promotion. 27 Adachi et al. considered active inflammation as a basic cause of recurrence: they found that in the liver with inflammatory changes, some adhesion molecules that adhered to cancer cells in the remnant liver after resection appeared and caused postoperative recurrence. 23 In this study, preoperative AST level was the variable most closely associated with disease-free survival and recurrence rate. This correlation was also strongly confirmed among HCV-positive patients, where the 5-year recurrence rate was significantly lower in the group with aminotransferase levels less than 80 U/L. In contrast, almost half of HCV-positive patients with a preoperative AST level higher than 2N suffered from a relapse of the disease. Several authors have reported that HCV-positive patients have a higher risk of developing HCC compared to HCV-negative patients because of the more intensive inflammation; 11, 31 we have shown that HCV-positive patients with high preoperative AST levels have the highest risk of postoperative recurrence. In HbsAg-positive patients, there is no difference in recurrence rate depending on aminotransferase levels, probably because of the small number of patients evaluated in this series.
To the best of our knowledge, this is the first report that correlates preoperative serum aminotransferase levels, as an index of hepatic inflammation, to recurrence rate among resected patients for HCC on cirrhosis in Western countries. Furthermore, we first evaluated the relationship between hepatocyte necrosis and tumor recurrence in HCV-positive and also in HBsAg-positive patients.
Anti-inflammatory drugs such as interferon or polyprenoic acid seem to reduce the incidence of HCC in patients with chronic active hepatitis or cirrhosis with vigorous necrosis. 26, 29, 32 Our results suggest that in cirrhotic patients with preoperative AST levels higher than 2N, suppression of the serum aminotransferase peak by adjuvant anti-inflammatory treatments may improve disease-free survival after liver resection and delay or prevent tumor recurrence. However, further randomized studies are needed to evaluate which drugs might be useful for this purpose. Alternatively, patients with intensive inflammatory activity, in particular HCV-positive patients, could be offered alternative treatments such as liver transplantation because of the high risk of disease relapse, as has already been proposed for patients with multiple lesions.
In conclusion, well-compensated cirrhotic patients with single lesions are good candidates for liver resection. Tumor recurrence is strictly linked to the status of underlying cirrhosis (related to both HBV and HCV), and a preoperative AST level equal to 2N seems to be a sensitive cutoff to stratify patients with different risk. Patients at high risk may benefit from adjuvant treatments with anti-inflammatory drugs. HCV-positive patients with preoperative aminotransferase levels greater than 2N show the highest risk of intrahepatic recurrence and should be closely monitored or referred for liver transplantation.
